Market Report Source

Overview

Introduction
This analysis examines the current position and future outlook for Pierre Fabre in the ethical pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase
Benchmark Pierre Fabre’s performance against key rivals in the ethical pharmaceutical sector
Learn how Pierre Fabre’s oncology franchise, driven by Javlor and Busulfex, will propel the company’s overall growth performance
Evaluate the strategies available to Pierre Fabre to sustain growth, capitalizing on its strong domestic position and driving international sales”

Table of Contents

TABLE OF CONTENTS

CHAPTER 1 EXECUTIVE SUMMARY

Key findings

Strategic outlook

Datamonitor’s strategic recommendations

Current positioning: competitive outlook 2004

Pierre Fabre’s forecast revenue stream, 2005–10

Key issues facing Pierre Fabre: 2005–10

CHAPTER 2 GLOBAL COMPANY STRATEGY

Introduction to Pierre Fabre

Small Pharma benchmarking of Pierre Fabre

Assessment of strategic position

Strengths

Weaknesses

Opportunities

Threats

Datamonitor’s strategic recommendations

Therapeutic foci

Evolution of R&D focus

Growth strategy assessment

Organic growth

Partnerships/licensing

Mergers and acquisitions

CHAPTER 3 GLOBAL PORTFOLIO AND PIPELINE ANALYSIS

Therapy area focus in 2004

Evolution of therapy area focus, 2004–10

Key growth drivers and resistors of future performance, 2005–10

Oncology franchise

Marketed products

R&D compounds

Oncology portfolio sales forecasts and forecast revenue growth

Cardiovascular franchise

Marketed products

R&D compounds

Cardiovascular portfolio sales forecasts and forecast revenue growth

Urology franchise

Marketed products

R&D compounds

Urology portfolio sales forecasts and forecast revenue growth

CNS franchise

Marketed products

R&D compounds

CNS portfolio sales forecasts and forecast revenue growth

Other products

Marketed products

R&D compounds

Other products sales forecasts and forecast revenue growth

CHAPTER 4 CORPORATE DEVELOPMENT

Financial position, 2003–04

Revenue growth

2004 performance benchmarking

Business model clustering according to 2003 R&D expenses and revenues

Corporate alliances and deals

Level of R&D investment

Regional distribution of revenues

CHAPTER 5 APPENDIX: SUPPORTING DATA

Exchange rates

LIST OF TABLES

Table 1: Small Pharma peer set

Table 2: Top 20 players in the French healthcare market, 2004

Table 3: Breakdown of Pierre Fabre’s ethical sales by therapy area, 2003–04

Table 4: Breakdown of Pierre Fabre’s ethical sales by therapy area, 2004–10

Table 5: Pierre Fabre’s marketed oncology portfolio

Table 6: Pierre Fabre’s current oncology R&D pipeline

Table 7: Forecast sales for Pierre Fabre’s oncology portfolio, 2005–10

Table 8: Pierre Fabre’s marketed cardiovascular portfolio

Table 9: Global statin market, 2004

Table 10: Pierre Fabre’s current cardiovascular R&D pipeline

Table 11: Forecast sales for Pierre Fabre’s cardiovascular portfolio, 2005–10

Table 12: Pierre Fabre’s marketed urology portfolio

Table 13: Global prostatic disease market, 2004

Table 14: Forecast sales for Pierre Fabre’s urology portfolio, 2005–10

Table 15: Pierre Fabre’s marketed CNS portfolio

Table 16: Pierre Fabre’s current CNS R&D pipeline

Table 17: Forecast sales for Pierre Fabre’s CNS portfolio, 2005–10

Table 18: Pierre Fabre’s other marketed products

Table 19: French oral anti-acne preparations market, 2003–04

Table 20: Pierre Fabre’s current other R&D products

Table 21: Forecast sales of Pierre Fabre’s other products portfolio, 2005–10

Table 22: Pierre Fabre’s revenues by division, 2003–04

Table 23: Summary of Pierre Fabre’s historical agreements, 2004–05

Table 24: R&D investment 2002–04

Table 25: Exchange rates*, 2004

LIST OF FIGURES

Figure 1: Assessment of Pierre Fabre’s strategic position, 2005

Figure 2: Competitive positioning of Pierre Fabre within the pharmaceutical market, 2004

Figure 3: Forecast sales for Pierre Fabre’s major therapy areas, 2005–10

Figure 4: Level of generic impact on Pierre Fabre’s therapy areas

Figure 5: Pierre Fabre’s level of R&D dependence

Figure 6: Total global revenues by company, 2001–10

Figure 7: Global revenue CAGRs by company, 2001–10

Figure 8: Development of Pierre Fabre’s therapeutic strategy, 2004–10

Figure 9: Pierre Fabre’s business development by therapy area

Figure 10: Pierre Fabre’s breakdown of corporate deals against the industry trend between January 2004 and May 2005

Figure 11: Pierre Fabre’s ethical sales breakdown, 2004–10

Figure 12: Pierre Fabre’s growth drivers and resistors, 2005–10

Figure 13: Sales of IV versus oral Navelbine, 2000–04

Figure 14: Competitive positioning of Pierre Fabre within the European pharmaceutical market, 2004

Figure 15: Pierre Fabre’s international distribution of revenues